KRAS and neoplasm: More potent KRAS G12C inhibitors rapidly emerged, and recently expanded phase I trials with sotorasib (AMG510) and adagrasib (MRTX849) have demonstrated tumor response rates of approximately 30% to 40% in lung cancer and a safe toxicity profile (4–6).